key: cord-1038966-nfem3htm authors: Nikniaz, L.; Akbarzadeh, M. A.; Hosseinifard, H.; Hosseini, M.-S. title: The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis date: 2021-01-05 journal: nan DOI: 10.1101/2021.01.04.21249219 sha: 577942eebe26cee7e0cc37fb5e211fdae4891b25 doc_id: 1038966 cord_uid: nfem3htm Background: Several studies have suggested the positive impact of vitamin D on patients infected with SARS-CoV-2. This systematic review aims to evaluate the effects of vitamin D supplementation on clinical outcomes and mortality rate of COVID-19 patients. Methods: A comprehensive search was conducted through the databases of PubMed, Scopus, Web of Knowledge, Embase, Ovid, and The Cochrane Library with no limitation in time and language, until December 16, 2020. The results were screened based on their accordance with the subject. Two independent reviewers selected the eligible studies and the outcomes of interest were extracted. Using the Joanna Briggs Institute (JBI) Critical Appraisal Tools for Randomized Controlled Trials (RCTs) and Quasi-Experimental Studies, the remaining results were appraised critically. Statistical analysis was performed using the Comprehensive Meta-Analysis (CMA) software version 2.0. Results: Of the 2311 results, 1305 duplicated results were removed. After screening the titles, abstracts, and the full-text articles of the remaining records, four studies and 259 patients were enrolled, including 139 patients in vitamin D intervention groups. In three of the studies, the patients' survival and mortality rate were evaluated. The pooled analysis of these studies showed a significantly lower mortality rate among the intervention groups (10.56%) compared with the control groups (23.88%) (OR = 0.264, 95% CI = 0.099-0.708, p-value = 0.008). Two of the studies reported the clinical outcomes based on the World Health Organization's Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19, where both of them showed a significant decrease in OSCI score in the vitamin D intervention groups. Additionally, One study reported a lower rate of intensive care unit (ICU) admission, and one study reported a significant decrease in serum levels of Fibrinogen. Conclusion: Prescribing vitamin D supplementation to patients with COVID-19 infection seems to decrease the mortality rate, the severity of the disease, and serum levels of the inflammatory markers. Further studies are needed to determine the ideal type, dosage and duration of supplementation. With the global widespread of the Severe acute respiratory syndrome coronavirus 2 (SARS- and the progressive rise in infection and mortality toll, efficient and effective management of the current medical emergency has become an absolute priority [1] . Great efforts have been taken in most of the involved countries to develop a comprehensive therapeutic approach to prevent and cure the disease. Considering the absence of definite treatment, the high number of the infected people, limited capacity of the healthcare centers, and extensive costs of providing treatments, the researchers and the clinicians are struggling to present appropriate clinical approaches w i t h favorable cost-benefit outcomes, which can help in both preventing the disease and treat the patients, along with lowering the burden of disease on the community [2, 3] . Since no safe medication has been developed yet, the search for the beneficial use of currently-available drugs has been prioritized. Therefore, different ways of improving the immune system's function have turned to a primary research goal. One of the potential candidates is vitamin D; a fat-soluble micronutrient that could possibly facilitate the function of the immune system [4, 5] . Although the emerging evidence is growing, a potential association between vitamin D deficiency and severe outcomes in patients with COVID-19 have been reported thus far [6, 7] . The immunomodulatory role of vitamin D has been investigated in the treatment of upper respiratory infections, even before the current pandemic [8] . Vitamin D and related metabolites have a regulatory role in the immune system, thanks to the common receptors found in various innate immune system cells [9, 10] . Furthermore, it can suppress the adaptive immune response in the affected areas (e.g., lung epithelial cells) and, consequently, avoid the proinflammatory agents' harm to prevent further damage [10] . Also, vitamin D plays a protective role against the direct damage of the inflammatory factors -which are secreted during the viral diseasesby lowering the expression rate of inflammatory factors, stimulating the expression of antiinflammatory factors, and more importantly stimulating the proliferation of the immune cells and their products [11] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint Since vitamin D has both stimulating and regulating effects on the immune system, it is reasonable to direct more attention to evaluating the in-hospital and home prescription of this supplement [12] . If the positive impact of vitamin D on COVID-19 patients gets confirmed, it can be used as a cheap and widely available therapeutic aid. Considering the probability of the addition of this supplement in treatment guidelines, it may be beneficial to evaluate the possible effects of vitamin D therapy on infected patients. According to the numerous evidence available and the lack of a systematic review in this field, this systematic review was conducted to evaluate the impact of prescribing vitamin D supplementation on mortality and clinical outcomes of COVID-19 patients. The current systematic review was conducted according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) [13] . The research question of the study was based on PICO and is available in Table 1 . Figure 1 presents the PRISMA Flow Diagram of the study. The study was approved by the Ethics Committee of Tabriz University of Medical Sciences, Tabriz, Iran. The current systematic review was designed and conducted in 2020. A comprehensive search was conducted among the databases of PubMed, Scopus, Web of Knowledge, Embase, Ovid, and The Cochrane Library, using a combination of the following free keywords and related MeSH (Medical All clinical trials, quasi-experimental, and pilot studies were included, if they administered any type of vitamin D supplementation to at least one group of confirmed COVID-19-positive patients, regardless of the number of patients, age groups, and language of the studies. Studies without vitamin D intervention and studies other than clinical trials, quasi-experimental, and pilot studies (e.g., casecontrol studies, cohort studies, observational studies, case reports, reviews, letter to editors, etc.), animal studies, and laboratory studies were excluded. In order to identify the studies relevant to the subject of the review, two researchers independently screened the results by title and abstract, according to their accordance with the study subject and the inclusion/exclusion criteria. Afterwards, the full-text of the remaining records were obtained and assessed for relevancy, and the remaining records were finally included in the study. Two independent researchers extracted the following data from the included studies: Author(s), year of publication, country of the study, mean ages, characteristics of the populations, type of intervention, and different outcomes. Two independent researchers critically appraised all included studies, using the Joanna Briggs Institute (JBI) Critical Appraisal Tools for Randomized Controlled Trials (RCTs) and Quasi-Experimental Studies. Statistical analysis was performed on the effect of vitamin D supplementation on the mortality rate, data of which was available in three of the studies, using the Comprehensive Meta-Analysis (CMA) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint software version 2.0. The odds ratio (OR) was calculated for each of the studies by events and total numbers of patients in two groups. The degree of heterogeneity was defined as significant with a pvalue less than 0.05 or I 2 over 50%. The pooled OR and the 95% confidence interval (95% CI) were calculated, and a p-value less than 0.05 was considered as statistically significant for outcomes. The results were presented as forest plot. Of the 2311 results, 1305 were removed due to the duplicity among different sources. After screening the titles and abstracts, 925 more studies were excluded due to incompatibility with the inclusion criteria. After reviewing the full-texts of the remaining records, 77 more records were excluded due to incompatibility of the study design with the inclusion criteria, and finally, four studies were critically appraised for risk of bias and all four were included in the current study. Figure 1 presents the PRISMA Flow Diagram of the study. Two of the studies were appraised by the JBI Critical Appraisal Tools for Randomized Controlled Trials (RCTs) and two of them by the JBI Critical Appraisal Tools for Quasi-Experimental Studies. All the appraised studies are reported as low-risk for bias in terms of having more low-risk domains than high-risk ones. Table 2 and Table 3 present the results of the quality assessment. The results of the risk of bias assessment are present in Table 2 and Table 3 . A total of 259 individuals (140 females and 119 males) were present in the included studies, 139 of which were allocated to the intervention groups. Two of the studies were conducted in France [14, 15] , one in India [16] and one in Spain [17] . From the four included studies, Three of the studies reported the mortality rate and survival, two of them reported the clinical outcomes based on the World Health Organization's Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19 [18], one of them reported the rate of intensive care unit (ICU) admission, and one of the studies . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint reported the changes of the inflammatory markers. Among the included studies, two studies were conducted among a population of aged patients (mean ages 87.7 and 88), and one study among vitamin D deficient patients (25(OH)D < 20 ng/mL). Bolus vitamin D3 was prescribed in three of the studies, two of them along with antibiotics, Hydroxychloroquine, and Corticosteroids (single-dose, oral route, 80.000 IU for one day), and one of them among the vitamin D deficient COVID-19 patients (oral route, 60.000 IU for seven day). In the study with vitamin D deficient patients, oral Cholecalciferol (60,000 IU) was prescribed for 7 days. The supplementation was continued to 14 days for the patients who did not reach the treatment goal of 25(OH)D > 50 ng/mL in the first seven days. From the baseline of 25(OH)D3 = 8.6 [7.1 -13.1] (ng/ml), the levels of 25(OH)D3 were increased to over 50 in ten patients after seven days of supplementation, and over 50 in two more patients after an overall of 14 days of supplementation. Along with Hydroxychloroquine and Azithromycin, oral Calcifediol was prescribed in one study by the following protocol: 0.532 mg on the day of admission, 0.266 mg on third and seventh days, and then 0.266 mg once every week. The characteristics of the included studies are presented in Table 4 . Three of the included studies reported the mortality rate. In the study of C. Annweiler et al. the mortality rate was 55.56% in the control group which was significantly (p = 0.023) higher than the intervention group (17.75%) during the follow-up time (36.6 ± 17 days) [14] . Hazard ratio (HR) for mortality in elderly COVID-19 patients, in accordance with the use of bolus vitamin D3 supplements was HR = 0.11 [95% CI: 0.03-0.48], which indicated that vitamin D supplementation is strongly more effective against mortality, compared with other interventions of the same study, including the use of corticosteroids (HR = 6.64), use of Hydroxychloroquine (HR = 15.07), use of antibiotics (HR = 0.36), and hospitalization (HR = 0.38). In another study, the mortality rate was 7.69% in the control group which was higher than the intervention group (0%), and the patients in the intervention group were all discharged without complications [17] . In the study of G. Annweiler et al., the mortality rate was 31.25% in the control group which was insignificantly (p = 0.28) higher than the intervention group (18.75%), showing a hazard ratio of 0.37 for 14-day mortality [15] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint As presented in Figure 2 , a meta-analysis was performed on the three studies reporting the mortality rate. The heterogenicity among the studies was not significant (Q = 1.514, df = 2, I 2 = 0.000, p-value = 0.469). The intervention group consisted of 123, and the control group consisted of 67 patients. Based on the results of the meta-analysis, vitamin D supplementation was associated with a significant reduction in the odds of mortality, compared with the control group (pooled OR =0.264, 95% CI = 0.099-0.708, p-value = 0.008). Only one study reported the Intensive Care Unit (ICU) admission [17] . The Intensive Care Unit (ICU) admission rate was 50% in the control group, in contrast with 2% in the intervention group. In this study, after performing a multivariate logistic regression analysis and adjusting the possible confounding effects on the admission to the ICU, an odds ratio (OR) of 0.03 (95% CI: 0.003 -0.25) was observed, in favor of no need for ICU admission. The World Health Organization's Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19 [18] was considered as a secondary outcome in two of the studies [14, 15] . The OSCI score was adjusted for participants' characteristics, and a significant decrease in the score was observed associated with the bolus supplementation of vitamin D (p = 0.001). The severity of disease was also assessed by the serum levels of inflammatory markers in one of the studies [16] . Unlike C-reactive protein (CRP), Procalcitonin, and D-dimer, the level of Fibrinogen was significantly decreased among the intervention group after the study duration (p-value = 0.007). To the best of our knowledge, this is the first systematic review exploring the effect of vitamin D supplementation on the mortality rate and clinical outcomes of COVID-19 patients. This review was conducted in order to clarify the effect of vitamin D supplementation on the clinical outcomes of the patients with COVID-19 infection, including the mortality rate, the severity of the disease, and the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; need for intensive care. Four studies [14] [15] [16] [17] , including 259 patients with COVID-19 infection, were included and assessed. Our analysis indicated that vitamin D supplementation could positively affect the mortality rate of COVID-19 patients. Moreover, vitamin D supplementation can significantly enhance the patients' survival, reduce the clinical complications, decrease ICU admission rate, and lower the serum levels of the inflammatory markers. Vitamin D is a micronutrient which has been investigated vastly due to its unique physiological impacts (i.e., regulating the endocrinological processes, the Renin-Angiotensin-Aldosterone-System Although the results are completely in favor of vitamin D, decreasing the mortality rate, an ultimate . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; 1 0 conclusion cannot be drawn due to the lack of studies. Also, the heterogenicity could be affected by the low number of studies. Moreover, some factors in the included studies could affect the patients' outcomes; two studies were conducted on the aged people, which might affect the mortality rate due to the presence of more comorbidities among the studied population. Similarly, one study was conducted on vitamin D-deficient patients which may show higher effectiveness of intervention, compared with an average population. Another factor that might affect the results is the difference in the dose of supplementation, which is inevitable due to the number of studies. However, the difference between these groups is in the etiology of the deficiency, which is due to lack of sun exposure and inadequate dietary intake among the young people, but rather physiologic among the aged people. Hence, both groups are disposed to the risk of severe outcomes of COVID-19. Apart from the etiology, the deficiency has a great impact on the strength of the immune system and therefore, leads to poor outcomes of COVID-19. A retrospective, multi-centric study conducted in the Philippines has demonstrated that in a population of 212 COVID-19 patients, patients with higher vitamin D levels had better outcomes [43] . Vitamin D receptors in the nuclei membrane regulate several defensive proteins and receptors -which are also effective against other viral infections [44] . Receptors recognize the pathogens, like viruses, and the interaction of vitamin D with these receptors could eventually affect the expression of their related genes [45] . In addition to these effects on the innate immune system, it also applies the regulatory impact on the adaptive immune system, which eventually results in inhibition of TH1 proliferation and shifting toward the proliferation of TH2, reduction of the oxidative compounds produced by TH1, influencing the maturation of the T-cells towards the anti-inflammatory subtypes, and prevent the further damage caused by the compounds [19, 46] . Regarding the inflammatory origin of COVID-19 clinical manifestations, it is beneficial further to evaluate inflammatory factors' role as relative prognostic factors [47] . Previous studies have indicated that several inflammatory markers like C-reactive protein (CRP), Interleukin 6 (IL-6), and erythrocyte sedimentation rate (ESR) have the potential to determine the prognosis and the severity of patients' clinical outcomes [48] [49] [50] [51] . Our study results showed that lower concentrations of these factors have been recorded among the patients who have consumed vitamin D supplementation. In one of the included studies, a significant decrease in Fibrinogen levels was observed after vitamin D supplementation. However, other the decrease in the evaluated inflammatory factors was not statistically significant. This could be explained according to the short follow-up duration and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint considering the fact that D-dimer, CRP, and ferritin have a relatively longer half-life and might need more time to reflect the impact. Therefore, it is important to determine extended follow-up durations in order to evaluate the paraclinical outcomes better. The main advantages of the current our systematic review are the rapid synthesis of the informationas the first systematic review on this topic, delivering the importance of further studies by highlighting the current clinical gaps, and providing clear instructions for further studies. The search of databases, study selection, study assessment, and data synthesis were based on defined criteria, and performed by two independent contributors, using the proper methodological tools. However, our review had some limitations. Prominently, the number of publications in the topic is low to draw precise conclusions. Moreover, although the reported heterogenicity was low, the results of the metaanalysis on mortality rate might still be affected by the low number of the included studies. Also, due to the lack of studies reporting the ICU admission and clinical outcomes, performing a quantitative analysis (meta-analysis) on these outcomes was impossible. Also, the difference in the dose of the administered supplementations might have affected the results. We strongly recommend performing further studies, especially clinical trials, on the current topic and among different patients' groups. Although some population-based studies have already shown the higher prevalence of severe outcomes among the vitamin D-deficient patients, still, we have insufficient evidence-based knowledge about the specific effects of vitamin D supplementation of COVID-19 patients, the impact on the infected patients' survival, mortality rate and disease progression, the possible side-effects, the proper dosage and route of prescription, the duration of the prescription course, and the potential prophylactic effects; which may be the most beneficial and practical application of vitamin D during this medical state of emergency. Vitamin D supplementation seems to decrease the mortality rate, the severity of the disease, and the inflammatory markers' levels among the COVID-19 infected patients, leading to a better prognosis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; and increased survival rate. More studies should be conducted to determine the optimum dosage and route of vitamin D supplementation and further investigate the potential prophylactic effects. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint 1 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. Table 3 . Quality assessment of the included randomized controlled trials. Was true randomization used for assignment of participants to treatment groups? Was allocation to treatment groups concealed? Were treatment groups similar at the baseline? Were participants blind to treatment assignment? Were those delivering treatment blind to treatment assignment? Were outcomes assessors blind to treatment assignment? Were treatment groups treated identically other than the intervention of interest? Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed? Were participants analyzed in the groups to which they were randomized? Were outcomes measured in the same way for treatment groups? Were outcomes measured in a reliable way? Was appropriate statistical analysis used? Overall appraisal is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. The rate of ICU-admission in the intervention group (2%) was lower than the control group (50%) (p < 0.001). No death was reported in the intervention group, while two of the control group patients died during their admission in the ICU. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2021. ; https://doi.org/10.1101/2021.01.04.21249219 doi: medRxiv preprint Figure 2 . Effect of vitamin D supplementation on the mortality rate of COVID-19 patients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 5, 2021. ; An evidence-based framework for priority clinical research questions for COVID-19 COVID 19 pandemic: perspectives on an unfolding crisis. The British journal of surgery What do we know about COVID-19? A review article Vitamin D and the immune system Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D The potential protective role of vitamin D supplementation on HIV-1 infection The possible double edged sword effects of vitamin D on COVID 19: A hypothesis Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Vitamin D and survival in COVID-19 patients: A quasi-experimental study Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study Short term, highdose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgraduate medical journal Perspective: Vitamin D deficiency and COVID 19 severity-plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19). Available at SSRN 3571484 Modulation of the immune response to respiratory viruses by vitamin D Vitamin D metabolism, mechanism of action, and clinical applications Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper Th17 to a Th2 and regulatory T cell profile Association of angiotensin converting The research protocol of this study was approved and supported by the Student Research Committee, Tabriz University of Medical Sciences (Grant number: 66884).